Global Peptide Based Infection Therapeutics Market Is Anticipated To Witness Significant Growth Owing To Rising Technological Advancements and Increasing Incidences of Chronic Diseases

 

Peptide Based Infection Therapeutics Market

Overview:

Synthetic peptide-based antiviral therapeutics are highly effective and safe, and can be manufactured easily and cost-effectively. Furthermore, they have broad applicability for a wide range of viral pathogens and are non-toxic. Food-derived antiviral peptides are another promising class of lead compounds for developing anti-b-CoV therapeutics. These peptides can bind with multiple viral proteins, including RBDs, NSPs, and host cell receptors. This can enhance their binding activity and sensitivity to the immune system. Researchers are exploring peptide-based vaccines for treating infectious disease. These peptide-based vaccines can be formulated to elicit protective immunity against multiple serotypes of a virus through conserved immunodominant epitopes.

Market Dynamics:

 

Growing technological advancements is estimated to augment growth of the global peptide based infection therapeutics market over the forecast period. For instance, an Ireland-based biotech company Nuratis, is using artificial intelligence (AI) technologies for detecting peptides effective against COVID-19 in April 2020. They took two initiatives for identifying the COVID-19. Moreover, increasing cost related with peptide drug discovery is anticipated to restrain growth of the global peptide based infection therapeutics market over the forecast period.

 

Impact of COVID-19:

 

The pandemic was declared as a public health emergency by the World Health Organization in January 2020. The virus was transmitted to many other countries worldwide and this led to imposition of strict restrictions in several nations. The pandemic led to halting of manufacturing activities around the world. Initially during the pandemic several clinical trials, and research activities were halted owing to strict government lockdown restrictions. However, many research institutes and organizations were conducting research on developing COVID-19 vaccines, and drugs, for battling the virus. Many peptide drugs were also used for treating COVID-19 patients during the pandemic. This had a positive impact on the growth of the global peptide based infection therapeutics market.

 

Key Takeaways:

 

The global peptide based infection therapeutics market is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing acquisitions by key players. For instance, a Germany-based pharmaceutical company Bayer acquired Vividion Therapeutics in August 2021. This acquisition will help in improving Bayer's drug discovery capabilities.

North America is anticipated to witness significant growth in the global peptide based infection therapeutics market over the forecast period, owing to increasing expansion of biotechnology and rising demand for cancer diagnostics.

Major players operating in the global peptide based infection therapeutics market are Novo Nordisk A/S, Eli Lilly and Company, Bristol-Myers Squibb, Pfizer, Inc., Bristol-Myers Squibb, Amgen, Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Lonza Inc., Teva Pharmaceuticals Industries Ltd.